ANDA 76151, held by Apotex. Diltiazem Hydrochloride.
As of Nov 16, 2026, ANDA 76151 (Dilt-Cd), held by Apotex, was first approved by FDA on May 20, 2004, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 20, 2004 | Original application | Approved |
| Dilt-Cd120MG · capsule, extended release;oral | Diltiazem Hydrochloride | Discontinued |
| Dilt-Cd180MG · capsule, extended release;oral | Diltiazem Hydrochloride | Discontinued |
| Dilt-Cd240MG · capsule, extended release;oral | Diltiazem Hydrochloride | Discontinued |
| Dilt-Cd300MG · capsule, extended release;oral | Diltiazem Hydrochloride | Discontinued |
| Jul 10, 2025 | Supplement 16Labeling · Standard review | Approved | None posted |
| Jul 10, 2025 | Supplement 17Labeling · Standard review | Approved | None posted |
| Jun 22, 2015 | Supplement 10Labeling · Standard review | Approved | None posted |
| Feb 28, 2012 | Supplement 9Labeling | Approved | None posted |
| May 20, 2004 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters